Osteoporosis in Men

Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a worldwide projection. Osteoporos Int 1992;2:285-9.10.1007/BF016231841421796Search in Google Scholar

Oden A, Dawson A, Dere W, Johnell O, Johnson B, Kanis JA. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998;8:599-603.10.1007/s00198005010510326067Search in Google Scholar

Poor G, Atkinson EJ, Lewallen DG, O'Fallon WM, Melton III LJ. Age related hip fractures in men: clinical spectrum and short-term outcome. Osteoporos Int 1995;5:419-26.10.1007/BF016266028695962Search in Google Scholar

Kanis JA, Johnell O, Oden A, Lindsay RL, Wahner HW, Dunn WL, Calvo MJ, Harris TB, Heyse SP. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000;11:669-74.10.1007/s00198007006411095169Search in Google Scholar

Looker AC, Orwoll ES, Johnston CC Jr, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Johnsson B. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-8.10.1359/jbmr.1997.12.11.17619383679Search in Google Scholar

Kaštelan D, Kujundžić Tiljak M, Kraljević I, Kardum I, Giljević Z, Koršić M. Calcaneus ultrasound in males - normative data in the Croatian population (ECUM study). J Endocrinol Invest 2006;29:221-5.10.1007/BF0334554316682834Search in Google Scholar

Frost ML, Blake GM, Fogelman I. Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporos Int 2000;11:321-30.10.1007/s00198007012110928222Search in Google Scholar

De Laet CEDH, van Hout BA, Burger H, Weel AEAM, Hofman A, Pols HAP. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998;13:1587-93.10.1359/jbmr.1998.13.10.15879783547Search in Google Scholar

Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J. Bone density variation and its effect on risk of vertebral deformity in men and women studied in thirteen european Centres: the EVOS Study. J Bone Miner Res 1997;12:1883-94.10.1359/jbmr.1997.12.11.18839383693Search in Google Scholar

Anderson FH, Francis RM, Selby PL, Cooper C. Sex hormones and osteoporosis in men. Calcif Tissue Int 1998;62:185-8.10.1007/s0022399004149501948Search in Google Scholar

Orwoll ES. Androgens. U: Bilezikian JP, Raisz LG, Rodan GR, urednici. Principles of Bone Biology. San Diego: Academic Press; 1996.Search in Google Scholar

Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC. Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens: the role of the androgen receptor. J Clin Invest 1989;95:2886-95.10.1172/JCI117995Search in Google Scholar

Gori F, Hofbauer LC, Conover CA, Khosla S. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 1999;140:5579-86.10.1210/endo.140.12.7213Search in Google Scholar

Khosla S, Melton III LJ, Riggs BL. Estrogen and the male skeleton. J Clin Endocrinol Metab 2002;87:1443-50.10.1210/jcem.87.4.8417Search in Google Scholar

Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly man. J Clin Endocrinol Metab 1999;84:3626-35.Search in Google Scholar

Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am 2003;32:25-38.10.1016/S0889-8529(02)00078-6Search in Google Scholar

Turner RT, Wakley GK, Hannon KS. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 1990;8:612-7.10.1002/jor.11000804182355301Search in Google Scholar

Kalender WA, Felsenberg D, Louis O. Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography. Eur J Radiol 1989;9:75-80.Search in Google Scholar

Aaron JE, Makins NB, Sagreiy K. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop 1987;215:260-71.10.1097/00003086-198702000-00038Search in Google Scholar

Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int 2004;75:100-9.10.1007/s00223-004-0289-415383923Search in Google Scholar

Ruff CB, Hayes WC. Sex differences in age-related remodeling of the femur and tibia. J Orthop Res 1988;6:886-96.10.1002/jor.11000606133171769Search in Google Scholar

Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999;84:3431-4.Search in Google Scholar

Kaštelan D, Giljević Z, Aganović I, Koršić M. Osteoporoza u muškaraca. Liječ Vjesn 2004;126:71-6.Search in Google Scholar

Ferrari S, Manen D, Bonjour JP, Slosman D, Rizzoli R. Bone mineral mass and calcium and phosphate metabolism in young men: relationships with vitamin D receptor allelic polymorphisms. J Clin Endocrinol Metab 1999;84:2043-8.10.1210/jc.84.6.2043Search in Google Scholar

Peris P, Alvarez L, Oriola J, Guanabens N, Monegal A, de Osaba MJ, Jo J, Pons F, Bellesta AM, Munoz-Gomez J. Collagen type 1 alpha 1 gene polymorphism in idiopathic osteoporosis in men. Rheumatology 2000;39:1222-5.10.1093/rheumatology/39.11.122211085801Search in Google Scholar

Kaštelan D, Grubić Z, Kraljević I, Đurić K, Kardum I, Dušek T, Štingl K, Giljević Z, Kerhin-Brkljačić V, Suchanek E, Koršić M. Decreased peak bone mass is associated with a 3-bp deletion/insertion of the CYP19 intron 4 polymorphism: a preliminary data from the GOOS study. J Endocrinol Invest (u tisku).Search in Google Scholar

Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.10.1210/jcem.83.7.4964Search in Google Scholar

Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N, Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol 1998;49:803-9.10.1046/j.1365-2265.1998.00631.xSearch in Google Scholar

Zmuda MJ, Cauley JA, Kuller LH, Ferrell RE. Androgen receptor CAG repeat length is associated with icreased hip bone loss and vertebral fracture risk among older men. J Bone Miner Res 2000;15(Suppl 1):491.10.1359/jbmr.2000.15.7.1417Search in Google Scholar

Scane AC, Francis RM. Risk factors for osteoporosis in men. Clin Endocrinol 1993;38:15-6.10.1111/j.1365-2265.1993.tb00965.xSearch in Google Scholar

Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly man. J Clin Endocrinol Metab 1999;84:3626-35.Search in Google Scholar

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Maskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.10.1016/S0140-6736(96)07088-2Search in Google Scholar

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.10.1001/jama.282.7.63710517716Search in Google Scholar

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni Mj, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999;282:1344-52.10.1001/jama.282.14.134410527181Search in Google Scholar

Neer RM, Arnaud CD, Zanchetta JR, Prince L, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41.10.1056/NEJM20010510344190411346808Search in Google Scholar

Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5.10.1210/jcem.86.11.798811701687Search in Google Scholar

Orwoll ES, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. New Engl J Med 2000;343:604-10.10.1056/NEJM20000831343090210979796Search in Google Scholar

Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.10.1359/jbmr.2003.18.1.9Search in Google Scholar

Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.10.1210/jc.85.9.3069Search in Google Scholar

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1897-9.10.1210/jc.2004-0952Search in Google Scholar

Finkelstein JS, Hayes A, Hunzelman JL, Wyland SS, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New Engl J Med 2003;349:1216-26.10.1056/NEJMoa035725Search in Google Scholar

Francis RM, Peacock M, Aaron JE, Selby PL, Taylor GA, Thompson J, Marshall DH, Horsman A. Osteoporosis in hypogonadal men: Role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption and low bone formation. Bone 1986;7:261-8.10.1016/8756-3282(86)90205-XSearch in Google Scholar

Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670-7.10.1210/jc.85.8.2670Search in Google Scholar

Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72.10.1210/jc.84.6.1966Search in Google Scholar

Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997;12:472-8.10.1359/jbmr.1997.12.3.4729076591Search in Google Scholar

Dalton JT, Mukherjee A, Zhu Z, Kirkovski L, Miller DD. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 1998;244:1-4.10.1006/bbrc.1998.82099514878Search in Google Scholar

Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull 2003;26:1563-9.10.1248/bpb.26.156314600402Search in Google Scholar

Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. An orally-active selective androgen receptor modulator is efficacious on bone, muscle and sex function with reduced impact on prostate. Endocrinology (u tisku).Search in Google Scholar

Kaštelan D, Giljević Z, Kraljević I, Koršić M. Selective estrogen receptor modulators: a possible new treatment of osteoporosis in males. Med Hypotheses 2006;67:1052-3.10.1016/j.mehy.2006.04.040Search in Google Scholar

Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841-6.10.1210/jc.2003-032058Search in Google Scholar

Kaštelan D, Koršić M. New hopes in the treatment of osteoporosis in men. Future Rheumatol (u tisku).Search in Google Scholar

Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiaition and activation. Cell 1998;93:165-76.10.1016/S0092-8674(00)81569-XSearch in Google Scholar

Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C, Sheng J. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004;34:656-64.10.1016/j.bone.2003.12.00615050896Search in Google Scholar

Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-9.Search in Google Scholar

Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001;411:321-5.10.1038/3507710811357136Search in Google Scholar

Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 2005;25:4946-55.10.1128/MCB.25.12.4946-4955.2005114057115923613Search in Google Scholar

Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD. Antibody-based inhibition of DKK1 supresses tumor-induced bone resorption and multiple myeloma growth in vivo.Blood (u tisku).Search in Google Scholar

Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Catham JA. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004;35:828-35.10.1016/j.bone.2004.05.02315454089Search in Google Scholar

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267-76.10.1093/emboj/cdg59929184014633986Search in Google Scholar

Beighton P, Barnard A, Hamersma H, van der Wouden A. The syndromic status of sclerosteosis and Van Buchem disease. Clin Genet 1984;25:175-81.10.1111/j.1399-0004.1984.tb00481.x6323069Search in Google Scholar

Warnington K, Morony S, Sarosi I. Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood. U: 27^th Annual Meeting of the American Society of Bone and Mineral Research; 23-27 Sep 2005. Nashville (TN), SAD. Sažetak.Search in Google Scholar

Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang JM, Tomaszek T, Yamashita DS, Marquis RW, Ol H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo monkeys. Bone (u tisku).Search in Google Scholar